Login to Your Account



Clinic Roundup


Monday, May 16, 2011
Ziopharm Oncology Inc., of New York, submitted an investigational new drug application for Ad-RTS-IL-12, a DNA-based therapeutic. The planned Phase I study will evaluate safety in additional to immunological and biological effects in patients with melanoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription